Tarsus Pharmaceuticals, Inc. — Director's Dealing 2023

Mar 22, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2023-03-17

Reporting Person: Whitfield Dianne C. (Chief Human Resources Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-17	Common Stock	S	316	$13.28	Disposed	12556	Direct
2023-03-20	Common Stock	S	333	$12.61	Disposed	12223	Direct

Footnotes

F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.